MAPT and Alzheimer disease: Inherent to using the AT(N) classification system, we dichotomized AT(N) biomarker data (CSF Aβ42, CSF p-tau and FDG-PET composite ROI) as +/− using cut-off values to classify participants as no Alzheimer’s disease pathology, suspected non-Alzheimer’s disease pathology or Alzheimer’s disease continuum, which may have led to loss of information.